EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy

Odunayo O Mugisho iD, Jyoti Aryal, Avik Shome, Heather Lyon iD, Monica L Acosta iD, Colin R Green iD, Ilva D Rupenthal iD

International Journal of Molecular Sciences · 15.02.2023 · 24 (4) · 3876

DOI: 10.3390/ijms24043876 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.02.2023. Verfasst von Odunayo O Mugisho und 6 weiteren Autor:innen. Beteiligte Einrichtung: Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, University of Auckland, Auckland 1023, New Zealand. Hauptthemen laut MEDLINE: Connexin 43, Diabetic Retinopathy, Benzamides. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Auckland Medical Research Foundation, Neurological Foundation of New Zealand, Neurological Foundation of New Zealand First Postdoctoral Fellowship 2001 FFE and an AMRF Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic retinopathy (DR), a microvascular complication of diabetes, is associated with pronounced inflammation arising from the activation of a nucleotide-binding and oligomerization domain-like receptor (NLR) protein 3 (NLRP3) inflammasome. Cell culture models have shown that a connexin43 hemichannel blocker can prevent inflammasome activation in DR. The aim of this study was to evaluate the ocular safety and efficacy of tonabersat, an orally bioavailable connexin43 hemichannel blocker, to protect against DR signs in an inflammatory non-obese diabetic (NOD) DR mouse model. For retina safety studies, tonabersat was applied to retinal pigment epithelial (ARPE-19) cells or given orally to control NOD mice in the absence of any other stimuli. For efficacy studies, either tonabersat or a vehicle was given orally to the inflammatory NOD mouse model two hours before an intravitreal injection of pro-inflammatory cytokines, interleukin-1 beta, and tumour necrosis factor-alpha. Fundus and optical coherence tomography images were acquired at the baseline as well as at 2- and 7-day timepoints to assess microvascular abnormalities and sub-retinal fluid accumulation. Retinal inflammation and inflammasome activation were also assessed using immunohistochemistry. Tonabersat did not have any effect on ARPE-19 cells or control NOD mouse retinas in the absence of other stimuli. However, the tonabersat treatment in the inflammatory NOD mice significantly reduced macrovascular abnormalities, hyperreflective foci, sub-retinal fluid accumulation, vascular leak, inflammation, and inflammasome activation. These findings suggest that tonabersat may be a safe and effective treatment for DR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Connexin 43Diabetic RetinopathyBenzamidesAnimalsMiceDisease Models, AnimalInflammasomesInflammationMice, Inbred NODNLR Family, Pyrin Domain-Containing 3 ProteinAdministration, OralBenzopyrans

Stichwörter der Autor:innen

diabetic retinopathyinflammasomeinflammationretinavascular breakdown

Substanzen

Connexin 43InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinBenzamidestonabersatBenzopyrans

Autor:innen und Institutionen

  • Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, University of Auckland, Auckland 1023, New Zealand.
  • School of Optometry and Vision Science, University of Auckland, Auckland 1023, New Zealand.
  • Department of Ophthalmology, University of Auckland, Auckland 1023, New Zealand.

ORCID-Profile: Odunayo O Mugisho, Heather Lyon, Monica L Acosta, Colin R Green, Ilva D Rupenthal

Förderung

  • Auckland Medical Research Foundation
  • Neurological Foundation of New Zealand
  • Neurological Foundation of New Zealand First Postdoctoral Fellowship 2001 FFE and an AMRF Project
  • W&B Hadden
  • Buchanan Charitable Foundation

Zitieren

APA

Mugisho, O. O., Aryal, J., Shome, A., Lyon, H., Acosta, M. L., Green, C. R., & Rupenthal, I. D. (2023). Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy. International Journal of Molecular Sciences, 24(4), 3876. https://doi.org/10.3390/ijms24043876

Vancouver

Mugisho OO, Aryal J, Shome A, Lyon H, Acosta ML, Green CR, et al. Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy. International Journal of Molecular Sciences. 2023;24(4):3876. doi:10.3390/ijms24043876

BibTeX
@article{Mugisho2023,
  author = {Mugisho, Odunayo O and Aryal, Jyoti and Shome, Avik and Lyon, Heather and Acosta, Monica L and Green, Colin R and Rupenthal, Ilva D},
  title = {Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {4},
  pages = {3876},
  doi = {10.3390/ijms24043876}
}
Kostenlos starten →